SPRC - What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? | Benzinga
SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration between the companies.
The Details:
SciSparc and Clearmind said the three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide.
“We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset,” said SciSparc’s CEO, Oz Adler.
“We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutic advantages,” Adler said.
“Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry. The PCT makes it possible for us to seek patent protection ...